Regeneron Pharmaceuticals (REGN) Return on Capital Employed (2010 - 2026)

Regeneron Pharmaceuticals' Return on Capital Employed history runs 17 years deep, the most recent figure standing at 10.19% for Q1 2026.

• On a quarterly basis, Return on Capital Employed fell 105.0% year-over-year to 10.19% in Q1 2026; TTM through Mar 2026 was 10.19%, a 105.0% decrease from a year earlier, with the FY2025 full-year figure at 10.28%, down 239.0% from the prior year.
• Return on Capital Employed grew to 10.19% in Q1 2026 per REGN's latest filing, from 9.94% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 39.73% in Q1 2022 and bottomed at 9.94% in Q4 2025.
• The 5-year median for Return on Capital Employed is 12.78% (2024), against an average of 16.26%.
• Biggest YoY gain for Return on Capital Employed was 1174 bps in 2022; the steepest drop was 2466 bps in 2022.
• Year by year, Return on Capital Employed stood at 18.73% in 2022, then retreated by 26 bps to 13.86% in 2023, then dropped by 14 bps to 11.86% in 2024, then dropped by 16 bps to 9.94% in 2025, then advanced by 3 bps to 10.19% in 2026.
• Per Business Quant, the three latest REGN Return on Capital Employed figures stand at 10.19% (Q1 2026), 9.94% (Q4 2025), and 10.61% (Q3 2025).